















HORMONAL CONTRACEPTION AND HIV 
BACKGROUND 
This brief was produced in collaboration with the U.S. President’s 
Emergency Plan for AIDS Relief (PEPFAR) and the Ofﬁce of Popu­
lation and Reproductive Health at the U.S.Agency for International 
Development (USAID).
What is the purpose of this brief? 
To summarize current epidemiological evidence regarding use of 
hormonal contraception (HC) and: 
• Whether HIV-negative women will acquire HIV 
• Whether women living with HIV will transmit HIV to their male 
sex par tner(s) 
• Whether women living with HIV will experience faster HIV 
disease progression 
• Whether women living with HIV using antiretroviral therapy 
(ART) will experience drug-drug interactions 
Who should read this brief? 
• National policy makers responsible for HIV and/or family plan­
ning programming 
• U.S. Government family planning and HIV program managers at 
headquar ters and in the ﬁeld 
• HIV and family planning implementing par tners 
COMMON METHODS OF HORMONAL CONTRACEPTION 
Type of Contraceptive Provision Frequency 
Oral contraceptive pills 
Combined oral contraceptive pill (“the pill”) Taken daily 
Progestin-only pill (POPs) Taken daily 
Progestogen-only injectables 
Depo medroxyprogesterone acetate (DMPA) Injected every 3 months 
Norethisterone enanthate (NET-EN) Injected every 2 months 
Long-acting contraceptive methods 
Implant Can last up to 5 years 
Levonorgestrel intrauterine device (hormonal IUD) Can last up to 5 years 
September 2013 
EVIDENCE AND RECOMMENDATIONS 
What published evidence and recommendations are
available regarding use of HC among HIV-negative
women? 
• HC use does not protect against HIV acquisition; all individuals at 
risk of HIV should be encouraged to use condoms consistently 
and correctly. 
• The most recent World Health Organization (WHO) guid­
ance (2012)1 recommends no restriction on the use of any HC 
method for women at high risk of HIV, and it contains a special 
clariﬁcation for women at high risk of HIV who use progestogen­
only injectable contraception, such as DMPA or NET-EN. 
1. Does use of an HC method increase a woman’s risk of HIV acquisition?
• Due to the inconclusive nature of the body of evidence on pos­
sible increased risk of HIV acquisition with use of progestogen­
only injectable contraception,2 women at high risk of HIV using 
progestogen-only injectable contraception should be strongly 
advised also to use condoms (male or female) consistently and 
correctly and to take other HIV preventive measures.1 
• Available data do not suggest an increased risk of HIV acquisition 
with use of oral contraceptive pills.2 
• There are limited data on whether methods such as contracep­
tive implants, patches, rings, or hormonal IUDs may or may not 
impact the risk of HIV acquisition.2 
• Improving and reinforcing messaging on dual method use (i.e.,
use of a condom plus a highly effective contraceptive) to simulta­
neously prevent unintended pregnancy and acquisition/transmis­
sion of sexually transmitted infections including HIV is critical. 
• Additional relevant evidence3-7 that has become available since 
the 2012 WHO guidance and that is published in the peer-
reviewed literature will be reviewed at the next WHO technical 
consultation, planned for 2014. This evidence will include:
 - Several sensitivity analyses conducted by Heffron et al. to ad­
dress concerns that their original estimates (which suggested a 
doubling of risk in HIV acquisition with use of injectable contra­
ception) may have been due to cer tain types of confounding 

























 -An analysis by McCoy et al. suggested that neither oral nor 
injectable contraceptives were signiﬁcantly associated with an 
increased risk of HIV acquisition, but the authors noted uncer­
tainty in the effect of injectable contraception on HIV risk.4 
What published evidence and recommendations 
are available regarding the use of hormonal contra­
ception for women living with HIV? 
• HC use does not protect against onward HIV transmission; all in­
dividuals living with HIV should be encouraged to use condoms 
consistently and correctly. 
• The most recent WHO guidance (2012) recommends no restric­
tion on the use of any HC method for women living with HIV.1 
1. Does use of an HC method increase the risk of female-to-male HIV 
transmission? 
• A systematic review8 identiﬁed one study9 among serodiscordant 
couples assessing oral contraceptive pills or injectable contra­
ception that suggested an increased risk of female-to-male HIV 
transmission with use of injectables. This study did not suggest 
a statistically signiﬁcant association between oral contraceptive 
pills and female-to-male HIV transmission.9 Additional studies 
explicitly designed to test if various forms of HC increase risk of 
female-to-male HIV transmission are needed.8 
• The systematic review also identiﬁed multiple studies assessing 
proxy measurements (e.g., genital HIV viral load or plasma HIV 
viral load) for HIV infectivity (e.g., the risk of transmitting HIV 
to an uninfected par tner) among women living with HIV using 
HC .These studies had mixed ﬁndings, with some suggesting 
evidence of increased infectivity with use of HC, some suggest­
ing evidence of decreased infectivity with use of HC, and some 
suggesting no effect.8 
• A recent publication suggests that the hormonal IUD does not 
increase HIV infectivity.10 
2. Does use of an HC method accelerate a woman’s rate of HIV 
disease progression? 
• The preponderance of evidence indicates no association be­
tween HC use and rate of HIV disease progression.11, 12 
3.Are drug-drug interactions expected for women living with HIV who 
use an HC method as well as ART? 
• Recent reviews suggest that cer tain ART medications (most 
likely protease inhibitors, the non-nucleoside reverse transcrip­
tase inhibitors efavirenz and nevirapine, and cobicistat-boosted 
elvitegravir) may potentially reduce the effectiveness of com­
bined oral contraceptives and possibly also of contraceptive 
implants.13, 14 
• DMPA and the hormonal IUD appear to maintain contracep­
tive efﬁcacy when taken with ART, though additional data are 
needed.13, 14 
• Women on ART who choose to use combined oral contracep­
tive pills or contraceptive implants should receive counseling 
on the potential reduced effectiveness of these methods when 
used simultaneously with cer tain ART regimens, and be offered 
alternative methods for their consideration. 
IMPLICATIONS FOR POLICIES AND PROGRAMS 
How can the global health community balance the
(potentially) competing risks of unintended preg­
nancy and HIV acquisition? 
• If a method of HC is found to increase HIV risk, this risk must be 
balanced against the life-saving beneﬁts of using highly effective 
contraceptive methods to prevent unintended pregnancy. 
• Recent modeling studies have, under the assumption that use of 
injectable contraception increases HIV risk, assessed the impact 
of reducing injectable contraceptive use on overall public health 
outcomes, including impacts on HIV infections and on maternal 
mor tality resulting from unintended pregnancy. 
• One such modeling study concluded,“Unless the true effect 
size approaches [a more than doubling in risk], it is unlikely that 
reductions in injectable hormonal contraception could result in a 
public health beneﬁt, with the possible exception of those coun­
tries in southern Africa with the largest HIV epidemics.”15 Other 
studies have reached generally similar conclusions.16-18 
• Thus, policy options that would result in the greatest public 
health beneﬁt depend not only upon the magnitude of any 
potential association between injectable contraception and HIV 
acquisition, but also on the epidemiological context of a given 
countr y, such as the HIV prevalence, the maternal mor tality rate,
the prevalence of injectable contraceptive use, and the contra­
ceptive method options available in that countr y. 
• Prevention of unintended pregnancy among women living with
HIV remains impor tant, so women living with HIV can better man­
age their right to choose the number, timing, and spacing of their
pregnancies, and in order to safeguard women’s and infants’ health,
including reducing ver tical (mother-to-child) transmission of HIV.
What does this evidence mean for policy makers 
and health care providers in general? 
• At the national policy and program strategy level, countries may 
consider :
 - Expanding access to HIV testing and counseling ser vices within 
family planning ser vice deliver y points, given the impor tance 
of knowing one’s HIV status in the selection of an appropriate 
contraceptive method19, 20
 -Utilizing the recent WHO HC-HIV guidelines1 to update or 
develop their own guidelines based on their national health 
policies, needs, priorities, resources, and epidemiological context
 - Broadening the contraceptive method mix to expand options 
























 - Ensuring that contraceptive counseling appropriately informs 
women of the risks and beneﬁts of all contraceptive methods 
to facilitate informed choice
 - Improving and reinforcing messaging on dual method use of a 
condom plus a highly effective contraceptive to simultaneously 
prevent unintended pregnancy and transmission/acquisition of 
sexually transmitted infections including HIV
 - Ensuring the availability and promotion of male and female 

condoms at family planning ser vice deliver y points
 
What does this evidence mean for policy makers 
and health care providers serving HIV-negative 
women? 
• Women at high risk of HIV infection can use all available HC 
methods. 
• As with anyone at high risk of HIV, women at high risk of HIV 
who select DMPA or NET-EN should be strongly advised to also 
use condoms (male or female) consistently and correctly and to 
also take other HIV preventive measures, such as ART initiation 
for HIV-positive par tners where appropriate, and potentially in 
the future, pre-exposure prophylaxis if this measure is adopted 
as par t of national guidelines. 
• Any potential increase in HIV acquisition risk with use of an HC 
method must be balanced against risks of:
 -Unintended pregnancy, including maternal morbidity and mor­
tality, unsafe abor tion, and infant mor tality
 -Any potential increase in risk of HIV acquisition that may pos­
sibly be associated with pregnancy itself 21-24 
• Family planning programs might consider this issue within the 
broader context of ensuring access to a wider contraceptive 
method mix and promoting universal coverage of voluntar y fam­
ily planning ser vices. 
What does this evidence mean for policy makers 
and health care providers serving women living 
with HIV? 
• Women living with HIV can use all available HC without con­
cerns related to HIV disease progression.
• Questions remain with respect to whether injectable contracep­
tion may increase the risk of HIV transmission to a male par tner.
As ART rollout increases, any such increased risk of HIV trans­
mission would be strongly decreased, since correct and consis­
tent ART use greatly reduces the chance of HIV transmission.25 
• Any potential increase in the risk of HIV transmission to men 
with use of an HC method must be balanced against:
 - Risk of unintended pregnancy, including maternal morbidity and 
mor tality, unsafe abor tion, and infant mor tality
 - Risk of unintended pregnancy and ver tical transmission from 
mother to child, which contributes to rates of pediatric HIV 
infection
 - Any potential increase in risk of female-to-male HIV transmis­
sion that may possibly be associated with pregnancy itself 21 
• Regardless of the contraceptive method used, women living with 
HIV should be counseled about the impor tance of combining 
their chosen method with effective HIV prevention inter ventions,
including condoms and ART initiation, and potentially in the fu­
ture, pre-exposure prophylaxis for their par tners if this measure 
is adopted as par t of national guidelines. 
• Women living with HIV should be counseled that cer tain ART 
regimens may render some HC methods (oral contraceptive 
pills and implants) less effective, but that ART is unlikely to have
an impact on the efﬁcacy of DMPA and hormonal IUDs. 
LOOKING FORWARD 
• The U.S. Government suppor ts research to develop safe, af­
fordable, acceptable, and accessible multipurpose prevention 
technologies to simultaneously prevent unintended pregnancies 
and acquisition of sexually transmitted infections, including HIV.
• The U.S. Government suppor ts research to improve knowledge 
on the potential link between HC and HIV;26 a collaborative 
working group is actively working on how to obtain more deﬁni­
tive evidence.
• The U.S. Government is suppor ting development of a communi­
cation tool for providers and policy makers on the issue of HC 
and HIV.
• The Ofﬁce of the Global AIDS Coordinator and USAID’s
Ofﬁce of Population and Reproductive Health will keep you in­








































   
 
  
    
 
   
 
   





• WHO Technical Statement on Hormonal Contracep­
tion and HIV, Februar y 2012: http://apps.who.int/iris/bit­
stream/10665/70811/1/WHO_RHR_12.08_eng.pdf 
• HIV and Hormonal Contraception, Frequently Asked Questions,
UNAIDS and WHO: http://www.who.int/reproductivehealth/pub­
lications/family_planning/FAQ_HIV_hormonal_contraception.pdf 
• PEPFAR FY2013 Technical Considerations (pages 273-281):
http://www.pepfar.gov/repor ts/guidance/technical/index.htm 
• PEPFAR FY2013 COP Guidance (pages 51-53): http://www. 
pepfar.gov/repor ts/guidance/cop2013/index.htm 
• PEPFAR Blueprint: http://www.pepfar.gov/documents/organiza­
tion/201386.pdf 
• UNFPA: Preventing HIV and Unintended Pregnancies: Strategic 
Framework 2013-2015: http://www.unfpa.org/webdav/site/global/ 
shared/documents/publications/2012/PreventingHIV_Unintend­
edPregnancies_SF2011_2015.pdf 
• UNFPA SRH & HIV Linkages Resource Pack:This site includes a 
variety of documents, searchable by topic area: http://www.srh­
hivlinkages.org/en/index.html 
• For more information on the contents of this brief, contact 
Dr. Chelsea Polis at cpolis@usaid.gov.
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